Emcure Pharmaceuticals Limited (IN:EMCURE)
:EMCURE
Want to see IN:EMCURE full AI Analyst Report?
EMCURE Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EMCURE Stock 12 Month Forecast
Average Price Target
₹1,970.00
▲(46.43% Upside)
| Highest Price Target₹1,970 | Average Price Target₹1,970 | Lowest Price Target₹1,970 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Jefferies
₹1,970
Buy
46.43%
Upside
Reiterated
05/08/26
Kotak Mahindra
₹1,710
Buy
27.10%
Upside
Reiterated
09/29/25
J.P. Morgan
₹1,350→₹1,550
Hold
15.21%
Upside
Reiterated
08/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
₹1,970
Buy
46.43%
Upside
Reiterated
05/08/26
Kotak Mahindra
₹1,710
Buy
27.10%
Upside
Reiterated
09/29/25
J.P. Morgan
₹1,350→₹1,550
Hold
15.21%
Upside
Reiterated
08/11/25
Best Analysts Covering Emcure Pharmaceuticals Limited
3 Months
Success Rate
4/7 ratings generated profit
Average Return
-1.53%
Copying Alok Dalal's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -1.53% per trade.
1 Year
Success Rate
7/7 ratings generated profit
Average Return
+18.00%
Copying Alok Dalal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.00% per trade.
2 Years
Success Rate
4/4 ratings generated profit
Average Return
+27.10%
Copying Alankar Garude's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EMCURE Analyst Recommendation Trends
Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
1
1
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
1
1
1
Each month's total comprises the sum of three months' worth of ratings.
EMCURE Financial Forecast
EMCURE Stock Forecast FAQ
What is IN:EMCURE’s average 12-month price target, according to analysts?
Based on analyst ratings, Emcure Pharmaceuticals Limited’s 12-month average price target is 1,970.00.
What is IN:EMCURE’s upside potential, based on the analysts’ average price target?
Emcure Pharmaceuticals Limited has 46.43% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Emcure Pharmaceuticals Limited a Buy, Sell or Hold?
Emcure Pharmaceuticals Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Emcure Pharmaceuticals Limited’s share price target?
The average share price target for Emcure Pharmaceuticals Limited is 1,970.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,970.00 ,and the lowest forecast is ₹1,970.00. The average share price target represents 46.43% Increase from the current price of ₹1,345.35.
The highest analyst share price target is ₹1,970.00 ,and the lowest forecast is ₹1,970.00. The average share price target represents 46.43% Increase from the current price of ₹1,345.35.
What do analysts say about Emcure Pharmaceuticals Limited?
Emcure Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of Emcure Pharmaceuticals Limited?
To buy shares of IN:EMCURE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.